MX2007004990A - Interferon beta desamidado. - Google Patents
Interferon beta desamidado.Info
- Publication number
- MX2007004990A MX2007004990A MX2007004990A MX2007004990A MX2007004990A MX 2007004990 A MX2007004990 A MX 2007004990A MX 2007004990 A MX2007004990 A MX 2007004990A MX 2007004990 A MX2007004990 A MX 2007004990A MX 2007004990 A MX2007004990 A MX 2007004990A
- Authority
- MX
- Mexico
- Prior art keywords
- deamidated
- interferon
- beta
- native
- protein
- Prior art date
Links
- 102000003996 Interferon-beta Human genes 0.000 title 1
- 108090000467 Interferon-beta Proteins 0.000 title 1
- 229960001388 interferon-beta Drugs 0.000 title 1
- 235000018102 proteins Nutrition 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000029983 protein stabilization Effects 0.000 abstract 1
- 238000003908 quality control method Methods 0.000 abstract 1
- 238000012113 quantitative test Methods 0.000 abstract 1
- 238000004007 reversed phase HPLC Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62683704P | 2004-11-10 | 2004-11-10 | |
| PCT/US2005/040758 WO2006053134A2 (en) | 2004-11-10 | 2005-11-10 | Deamidated interferon-beta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007004990A true MX2007004990A (es) | 2007-06-14 |
Family
ID=36337216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007004990A MX2007004990A (es) | 2004-11-10 | 2005-11-10 | Interferon beta desamidado. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7595040B2 (enExample) |
| EP (1) | EP1809662B1 (enExample) |
| JP (1) | JP4891250B2 (enExample) |
| KR (1) | KR101330626B1 (enExample) |
| CN (1) | CN101056890B (enExample) |
| AT (1) | ATE415421T1 (enExample) |
| AU (1) | AU2005304486B2 (enExample) |
| BR (1) | BRPI0517697A (enExample) |
| CA (1) | CA2587061C (enExample) |
| DE (1) | DE602005011321D1 (enExample) |
| ES (1) | ES2318575T3 (enExample) |
| MX (1) | MX2007004990A (enExample) |
| PL (1) | PL1809662T3 (enExample) |
| PT (1) | PT1809662E (enExample) |
| RU (1) | RU2404190C2 (enExample) |
| WO (1) | WO2006053134A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| AU2007284964A1 (en) * | 2006-08-08 | 2008-02-21 | Novartis Ag | Recombinant interferon-beta with enhanced biological activity |
| CN101675071B (zh) | 2007-05-02 | 2014-06-18 | Ambrx公司 | 经修饰干扰素β多肽和其用途 |
| EP2207890A4 (en) * | 2007-10-05 | 2010-12-15 | Barofold Inc | HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS |
| ES2736503T3 (es) * | 2014-04-04 | 2020-01-02 | Ares Trading Sa | Nuevos análogos de la proteína IFN beta |
| RU2739261C1 (ru) * | 2019-12-31 | 2020-12-22 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ количественного определения антипролиферативной активности интерферона-бета человека |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4737462A (en) * | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| GB9111902D0 (en) * | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
| US20030190307A1 (en) * | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| DE69729880T3 (de) | 1996-12-24 | 2012-05-10 | Biogen Idec Ma Inc. | Stabile flüssige interferon-zubereitungen |
| US6696423B1 (en) * | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| DK1017413T4 (da) * | 1997-09-23 | 2008-03-25 | Rentschler Biotech Gmbh | Flydende formulering af interferon-beta |
| JP2003508028A (ja) * | 1999-07-28 | 2003-03-04 | ジェネンテック・インコーポレーテッド | 腫瘍治療のための組成物と方法 |
| ES2180416B1 (es) * | 2001-03-12 | 2004-06-01 | BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. | Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen. |
| UY27373A1 (es) * | 2001-07-09 | 2003-02-28 | Schering Ag | Formulaciones de interferón beta-humano |
| RU2216345C1 (ru) * | 2002-03-21 | 2003-11-20 | Закрытое Акционерное Общество "Биокад" | Средство, обладающее иммуномодулирующим, противовирусным, противобактериальным, регенерирующим, репаративным, мембрано- и гепатопротекторным действием |
| KR100541850B1 (ko) | 2003-03-31 | 2006-01-11 | 삼성정밀화학 주식회사 | 인간 인터페론-베타 변이체 및 그의 제조방법 |
-
2005
- 2005-11-10 DE DE602005011321T patent/DE602005011321D1/de not_active Expired - Lifetime
- 2005-11-10 CA CA2587061A patent/CA2587061C/en not_active Expired - Fee Related
- 2005-11-10 PL PL05818235T patent/PL1809662T3/pl unknown
- 2005-11-10 MX MX2007004990A patent/MX2007004990A/es active IP Right Grant
- 2005-11-10 JP JP2007540208A patent/JP4891250B2/ja not_active Expired - Fee Related
- 2005-11-10 PT PT05818235T patent/PT1809662E/pt unknown
- 2005-11-10 ES ES05818235T patent/ES2318575T3/es not_active Expired - Lifetime
- 2005-11-10 KR KR1020077011869A patent/KR101330626B1/ko not_active Expired - Fee Related
- 2005-11-10 CN CN2005800381182A patent/CN101056890B/zh not_active Expired - Fee Related
- 2005-11-10 AU AU2005304486A patent/AU2005304486B2/en not_active Ceased
- 2005-11-10 EP EP05818235A patent/EP1809662B1/en not_active Expired - Lifetime
- 2005-11-10 US US11/271,516 patent/US7595040B2/en not_active Expired - Fee Related
- 2005-11-10 RU RU2007121515/04A patent/RU2404190C2/ru not_active IP Right Cessation
- 2005-11-10 BR BRPI0517697-2A patent/BRPI0517697A/pt not_active IP Right Cessation
- 2005-11-10 AT AT05818235T patent/ATE415421T1/de active
- 2005-11-10 WO PCT/US2005/040758 patent/WO2006053134A2/en not_active Ceased
-
2009
- 2009-03-25 US US12/410,540 patent/US20090263355A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005304486B2 (en) | 2011-08-11 |
| PT1809662E (pt) | 2009-02-26 |
| BRPI0517697A (pt) | 2008-10-14 |
| DE602005011321D1 (de) | 2009-01-08 |
| CA2587061C (en) | 2011-08-16 |
| JP4891250B2 (ja) | 2012-03-07 |
| RU2007121515A (ru) | 2008-12-20 |
| WO2006053134A2 (en) | 2006-05-18 |
| RU2404190C2 (ru) | 2010-11-20 |
| PL1809662T3 (pl) | 2009-07-31 |
| US20060120998A1 (en) | 2006-06-08 |
| US7595040B2 (en) | 2009-09-29 |
| ATE415421T1 (de) | 2008-12-15 |
| KR101330626B1 (ko) | 2013-11-18 |
| AU2005304486A1 (en) | 2006-05-18 |
| JP2008519769A (ja) | 2008-06-12 |
| CN101056890A (zh) | 2007-10-17 |
| CA2587061A1 (en) | 2006-05-18 |
| CN101056890B (zh) | 2012-05-09 |
| KR20070084559A (ko) | 2007-08-24 |
| ES2318575T3 (es) | 2009-05-01 |
| WO2006053134A3 (en) | 2006-08-31 |
| EP1809662A2 (en) | 2007-07-25 |
| EP1809662B1 (en) | 2008-11-26 |
| US20090263355A1 (en) | 2009-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007434A (es) | Peptidos de colageno producidos de forma sintetica y recombinante con eficacia biologica. | |
| DE602004012424D1 (de) | Homogene herstellungen von il-29 | |
| ATE430197T1 (de) | Fibroblasten wachstumsfaktor-ähnliche polypeptide | |
| NO2017028I1 (no) | eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet. | |
| BRPI0514790A (pt) | muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano | |
| ATE417595T1 (de) | Keratin-bindende polypeptide | |
| BRPI0416683A (pt) | muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21 | |
| WO2006005140A3 (en) | Proteinaceous compounds and uses therefor | |
| NZ279963A (en) | Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946 | |
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| PL1809662T3 (pl) | Dezamidowany interferon-beta | |
| MX2009001348A (es) | Interferon-beta recombinante con actividad biologica mejorada. | |
| WO2008041014A3 (en) | Interferon- alpha constructs for use in the treatment of diseases characterised by abnormal cell proliferation such as cancer | |
| ATE493966T1 (de) | Mittel zur förderung der hautkollagenproduktion | |
| NZ562436A (en) | Toll-like receptor 14 (TLR14) and use thereof | |
| MX2009007248A (es) | Peptidos bio-activos cortos para modulacion celular e inmunologica. | |
| ATE362535T1 (de) | Mutiertes cyclin g1 protein | |
| TW200722104A (en) | Low-toxicity, long-circulating human interferon-α analogs | |
| ATE420890T1 (de) | Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide | |
| WO2006025995A3 (en) | Compositions and methods using md-2 mutants and chimeric proteins | |
| ATE538806T1 (de) | Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren | |
| ATE475099T1 (de) | Beurteilung der biologischen aktivität von hgf (hepatocyte growth factor) | |
| ATE387494T1 (de) | Hitzelabile desoxyribonuklease i-varianten | |
| ATE423200T1 (de) | Neues plexin-polypeptid, dieses codierende dna und verwendung davon | |
| WO2003087318A3 (en) | Truncated 24 kda basic fibroblast growth factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |